ACTU

HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a Buy recommendation.

Analyst Price Forecast Suggests 181.38% Upside

As of March 4, 2025, the average one-year price target for Actuate Therapeutics is $20.40/share. The forecasts range from a low of $20.20 to a high of $21.00. The average price target represents an increase of 181.38% from its latest reported closing price of $7.25 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual non-GAAP EPS is -1.22.

What is the Fund Sentiment?

There are 26 funds or institutions reporting positions in Actuate Therapeutics. This is an increase of 15 owner(s) or 136.36% in the last quarter. Average portfolio weight of all funds dedicated to ACTU is 3.24%, an increase of 2,820.41%. Total shares owned by institutions increased in the last three months by 2,555.72% to 10,149K shares.

What are Other Shareholders Doing?

ACTU / Actuate Therapeutics, Inc. Shares Held by Institutions

BIOS Capital Management holds 9,894K shares representing 50.65% ownership of the company.

Voss Capital holds 55K shares representing 0.28% ownership of the company.

Geode Capital Management holds 28K shares representing 0.14% ownership of the company. No change in the last quarter.

Northwestern University holds 28K shares representing 0.14% ownership of the company. No change in the last quarter.

Mercer Global Advisors holds 16K shares representing 0.08% ownership of the company.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.